ZyVet® launches affordable Furosemide tablets to support long-term heart care trusted diuretic for dogs and cats now available in a generic form

ZyVet® Animal Health, a leader in affordable generic pharmaceuticals for animals and a wholly owned subsidiary of Zydus Pharmaceuticals (USA) Inc., itself a wholly owned subsidiary of Zydus Lifesciences Ltd., a global innovation led healthcare company, announces the launch of first veterinary approved generic of Furosemide Tablets, a critical therapy for managing congestive heart failure and chronic fluid retention in dogs and cats.

Furosemide remains the most widely used veterinary diuretic for reducing edema and pulmonary congestion due to cardiac, renal, or systemic disease. ZyVet's formulation offers veterinarians a consistent, cost-effective solution that supports long-term therapy, without compromising dosing flexibility or product availability.

Speaking on this development, Punit Patel, President and CEO, Zydus Americas, said, "We are happy to participate in the animal health segment and launch the first approved generic of Furosemide in the US. Managing chronic conditions in pets is a long journey, and consistency in care makes all the difference. At ZyVet, we believe in ensuring that veterinarians and pet owners have reliable, affordable options they can count on, and this launch is another step toward making quality drugs accessible to all."

"Heart failure and chronic fluid retention require lifelong management, and that often means long-term medication," said Punit Patel. "By offering Furosemide as part of our trusted portfolio, we're helping veterinary teams maintain continuity of care while supporting client adherence. Our goal is to make innovation affordable and ensure veterinarians and pet owners have high-quality products they can count on, without cost or supply concerns that too often disrupt care. ZyVet was launched with the belief that veterinarians and pet owners shouldn't have to choose between cost and care. Our Furosemide tablets are another step toward making clinical innovation affordable."

Manufactured under stringent quality standards, ZyVet's Furosemide tablets are available in multiple strengths to accommodate patient-specific dosing. As with all ZyVet products, the new formulation reflects the company's commitment to providing veterinarians and pet owners with much needed alternatives to higher-cost pioneer drugs.

ZyVet's expanding product portfolio supports a growing paradigm shift in the veterinary pharmaceutical market, where access to generic options remains limited despite increasing demand. Fewer than 20% of products in animal health have generic equivalents - yet the need for affordable, high-quality products is growing.

With Furosemide, ZyVet launches another first to market veterinary generic pharmaceutical and strengthens its rapidly growing presence in the animal health pharmaceutical market. As the dedicated animal health division of Zydus Lifesciences, ZyVet benefits from more than 70 years of pharmaceutical R&D, Regulatory, QA/QC, and Manufacturing scale, excellence and expertise.

Shares of Zydus Lifesciences Limited was last trading in BSE at Rs. 1035.00 as compared to the previous close of Rs. 1036.70. The total number of shares traded during the day was 18100 in over 1216 trades.

The stock hit an intraday high of Rs. 1043.35 and intraday low of 1030.00. The net turnover during the day was Rs. 18761211.00.

Source : Equity Bulls

Keywords

ZydusLifesciences INE010B01027 Pharmaceuticals ZyVetAnimalhealth ZydusPharmaceuticalsUSAInc FurosemideTablets